Currently accepted at: JMIR Medical Informatics
Date Submitted: May 5, 2026
Date Accepted: Nov 16, 2026
This paper has been accepted and is currently in production.
It will appear shortly on 10.2196/100411
The final accepted version (not copyedited yet) is in this tab.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Are Existing AI Laws Sufficient to Address Emerging Threats in Healthcare AI?
ABSTRACT
Artificial intelligence (AI) in health care has progressed from experimental promise to extensive clinical infrastructure. AI systems now influence disease diagnosis, patient triage, and treatment. However, the legal architecture that regulates these systems remains fragmented and reactive. In this article we discuss that despite a few important landmarks, like the EU Artificial Intelligence Act, and anti-discrimination provisions in U.S. federal health law, current statutes and regulations are not yet adequate to address technical and sociotechnical risks associated with contemporary and foundation-model-driven health AI. Closing this gap requires outcome-anchored oversight across the full lifecycle of AI development which includes mandatory post-deployment auditing, explicit sharing of liability across multi-actor in the AI supply chains, and testbed-based evaluation in the settings where such systems are intended to be used. These proposals are consistent with the ethos of CONSORT-AI, SPIRIT-AI, and TRIPOD-AI, which should have statutory force.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.